More Than Just Feeling Warm
Hot flashes — or hot flushes, as they’re called in many other countries — are the most iconic symptom of menopause. Virtually every woman who hears ‘menopause’ pictures a sudden wave of heat, a flushed face, and maybe a slightly frantic search for the nearest fan. But there’s a lot more to this symptom than its cultural caricature suggests. For many women, hot flashes are seriously disruptive — affecting sleep, concentration, work performance, relationships, and quality of life. And they deserve to be treated, not simply endured.
At our gynecology practice serving Sugar Land and Missouri City, we take a comprehensive, evidence-based approach to managing vasomotor symptoms. Let’s break down exactly what’s happening in your body during a hot flash and review the full menu of treatment options — because there are more than most women realize.
The Biology of a Hot Flash
Hot flashes are technically called vasomotor symptoms (VMS) because they involve the dilation of blood vessels close to the skin surface — producing that characteristic flush and sweat. The underlying mechanism begins in the hypothalamus, the part of the brain that acts as the body’s thermostat.
In reproductive-aged women, the hypothalamus maintains a ‘thermoneutral zone’ — a comfortable temperature range within which the body doesn’t need to trigger cooling responses. When core body temperature moves above this zone, the hypothalamus triggers sweating and blood vessel dilation to cool the body down. With declining estrogen, this thermoneutral zone narrows significantly — meaning even tiny fluctuations in core temperature can trigger a full-blown cooling response. The result: hot flashes from temperature changes that wouldn’t have bothered you before.
The key molecular driver of this process has been identified as neurokinin B, a neuropeptide that stimulates certain neurons in the hypothalamus. Estrogen normally suppresses this pathway — when estrogen falls, neurokinin B signaling increases, lowering the threshold for triggering vasomotor responses. This discovery led to the development of a new class of non-hormonal treatment: neurokinin 3 receptor (NK3R) antagonists.
What Hot Flashes Feel and Look Like
Typically, a hot flash begins with a sudden sensation of warmth or heat spreading across the face, neck, and chest. The skin may become visibly red. Sweating follows, sometimes profusely. Heart rate often increases. Some women feel anxious during a hot flash. After the acute warmth subsides — usually within one to five minutes — a chill often follows as the sweating cools the body below normal temperature. Night sweats are essentially hot flashes occurring during sleep, often waking women repeatedly.
Hot flash frequency varies enormously. Some women have a handful per day. Others report 15 or more per day — a frequency that truly constitutes a medical problem impacting every area of functioning. Research shows that up to 80 percent of perimenopausal and menopausal women experience VMS, and about 25 to 30 percent describe them as severely bothersome. The duration of VMS also varies — the median duration is about seven years, but a substantial proportion of women experience hot flashes for ten years or more.
Why Hot Flashes Matter Beyond Comfort
While quality of life is reason enough to treat VMS, there’s growing evidence that persistent, severe hot flashes may have independent health consequences. Research has linked frequent and severe vasomotor symptoms to higher cardiovascular risk markers — including increased carotid intima-media thickness (an early measure of arterial disease), adverse changes in lipid profiles, and increased insulin resistance. Hot flashes have also been associated with decreased bone mineral density and increased fracture risk. Sleep disruption from night sweats adds its own health burden through chronic sleep deprivation. These findings reinforce that treating VMS is not merely cosmetic — it may have genuine long-term health implications.
Hormone Therapy: The Most Effective Option
The 2022 NAMS Hormone Therapy Position Statement — the gold standard reference document from the North American Menopause Society — is clear: hormone therapy (HT) is the most effective treatment for vasomotor symptoms, and for most healthy women under 60 or within 10 years of menopause onset, the benefits outweigh the risks. This is an important reframing from the fear that gripped hormone therapy prescribing following the Women’s Health Initiative (WHI) study in 2002.
The WHI results were broadly misapplied for years. The average age of women in the WHI was 63 — more than a decade past menopause onset. The risk-benefit profile for women starting HT closer to the menopause transition (within 10 years) is significantly more favorable — a concept now called the ‘timing hypothesis’ or ‘window of opportunity.’ Research including the KEEPS (Kronos Early Estrogen Prevention Study) and ELITE (Early versus Late Intervention Trial with Estradiol) studies support the safety and benefit of HT when started in recently menopausal women.
Transdermal estrogen (patches, gels, sprays) appears to carry lower risks of blood clots and stroke than oral estrogen, because it bypasses first-pass liver metabolism. For women who still have a uterus, a progestogen must be added to protect the endometrium from the growth-stimulating effects of estrogen alone. Micronized progesterone (Prometrium) is the preferred formulation for most women because of its favorable safety profile.
Fezolinetant: The New Non-Hormonal Option
In May 2023, the FDA approved fezolinetant (brand name Veozah) — the first in a new class of non-hormonal medications specifically designed to treat moderate to severe menopausal hot flashes. Fezolinetant is a selective neurokinin 3 receptor (NK3R) antagonist. By blocking the NK3 receptor in the hypothalamus, it interrupts the signaling pathway that triggers VMS — addressing the problem at its biological root rather than simply replacing estrogen.
In the SKYLIGHT clinical trials, fezolinetant 45 mg daily significantly reduced hot flash frequency and severity compared to placebo. It’s an important option for women who cannot or prefer not to use hormone therapy — including breast cancer survivors and women with certain cardiovascular risk factors. Fezolinetant requires some monitoring for liver function and cannot be combined with certain medications (specifically CYP1A2 inhibitors). Your gynecologist can determine whether it’s appropriate for you.
SSRIs, SNRIs, and Gabapentin
Several non-hormonal prescription medications have evidence for reducing hot flash frequency and severity. These are recommended in the NAMS 2023 Nonhormone Therapy Position Statement for women who can’t or prefer not to use hormone therapy or fezolinetant.
Low-dose paroxetine mesylate (Brisdelle, 7.5 mg) is the only SSRI with an FDA approval specifically for menopausal hot flashes. Other SSRIs and SNRIs — including escitalopram, venlafaxine, and desvenlafaxine — also have good evidence for reducing VMS, though they are used off-label for this purpose. These medications are useful for women who also have depression or anxiety, since they address both simultaneously.
Gabapentin, primarily an anticonvulsant and nerve pain medication, reduces hot flash frequency and is particularly helpful for women whose hot flashes are predominantly at night (since it also promotes sleep). It’s used at lower doses for VMS than for pain or seizures. Oxybutynin, typically used for overactive bladder, has also shown modest benefit for VMS.
Lifestyle Measures That Make a Difference
While lifestyle changes alone are rarely sufficient for moderate to severe hot flashes, they can meaningfully complement other treatments and may be enough for mild symptoms. Keeping the bedroom cool, using layered bedding, wearing moisture-wicking clothing, dressing in layers during the day, and carrying a portable fan are practical strategies that reduce hot flash impact.
Cognitive-behavioral therapy (CBT) has Level I evidence from the NAMS guidelines for reducing the distress and impact of hot flashes, even when it doesn’t reduce frequency. Clinical hypnosis also has strong evidence for VMS relief. Weight loss in overweight women appears to reduce hot flash frequency. Reducing alcohol and spicy food consumption — known triggers for many women — can also help, as can quitting smoking.
What Doesn’t Have Strong Evidence
It’s worth being honest about this, because the wellness industry aggressively markets supplements and products to menopausal women. Phytoestrogens (soy isoflavones, black cohosh), herbal supplements, and many other marketed menopause products have weak, inconsistent, or absent evidence from well-designed clinical trials. The NAMS guidelines do not recommend them as first-line treatments. Some may have minor benefits for certain individuals, but they should not replace evidence-based care, and they should be disclosed to your gynecologist as some can interact with medications.
You Have Options
The landscape of hot flash treatment has genuinely expanded in recent years, with new options like fezolinetant joining a well-established toolkit of hormonal and non-hormonal strategies. No woman should feel she has to simply white-knuckle it through hot flashes. Our team in Sugar Land and Missouri City is here to help you find the right approach for your health history, preferences, and symptom severity.
